Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
AZD0022 | 可口服和选择性的KRAS G12D抑制剂 | 抗肿瘤 | TargetMol
AZD0022 | KRas inhibitor | CAS 2958627-18-2 | Selleck
AZD0022
AZD0022 | KRAS G12D inhibitor | Probechem Biochemicals
AZD0022 Explained: How AstraZeneca’s New Drug Could Transform Cancer ...
AZD0022 CAS#: 2958627-18-2
Study on the Safety and Effectiveness of AZD0022 Alone and with Other ...
AZD0022 是一种选择性具有口服活性的 KRASG12D 抑制剂 | MedChemExpress
阿斯利康KRAS G12D抑制剂AZD0022在中国申报临床，拟开发治疗实体瘤
AZD-0022 - Chemietek
TiPLab - 2025AACR年会揭晓的12种新型抗癌药物之：下一代精准KRAS小分子抑制剂
快讯｜2025年AACR年会上，首次披露值得关注的活性分子！ - 知乎
阿斯利康 5 款 1 类新药首次在中国获批临床
Wafik S. El-Deiry: Dr. Susan Galbraith speaks about AstraZeneca ...
Abstract ND11: AZD0022: a potent, oral KRASG12D-selective inhibitor ...
#medicine #aacr25 #pharmaceuticals #healthcare | Chris De Savi | 13 ...
祐森健恒许可给阿斯利康的KRAS G12D抑制剂在中国获批临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
【AZD0022】大腸がん、膵がん、非小細胞肺がん / 第I相試験 / KRASG12D阻害剤 | 国立がん研究センター中央病院 先端医療科 ...
科学网—2025 AACR 大会：星光闪耀下的明星分子与关键分子砌块揭秘 | 乐研试剂 - 陈谦的博文
AZD-0022(AZD-0022) - 药物靶点：KRAS G12D_专利_临床_研发
AZD2389
A Phase I/IIa Study to Investigate the Safety, Tolerability ...
Multiple Strategies to Develop Small Molecular KRAS Directly Bound ...
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates ...
Ondansetron Orally Disintegrating Tablets (ODT) 4mg Tablets, - Penn ...
AACR 2024：KRAS抑制剂最新进展 - 知乎
Structure-Based Design and Synthesis of Potent and Selective KRAS G12D ...
Frontiers | Transition-metal-catalyzed synthesis of quinazolines: A review
KRAS G12D: The Next Frontier in Cancer Therapy | MedChemExpress
阿斯利康(AZN.US)KRAS G12D抑制剂在华获批临床_腾讯新闻
2025 美国癌症研究协会年会：12 种创新肿瘤药物亮相
KRAS G12D Inhibitor Molecule Overview | Lilly Oncology
$加科思-B(01167)$ 阿斯利康KRAS G12D抑制剂在中国申报临床原创 医药观澜 2024年11月13日 1... - 雪球
Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor ...
Nat Rev Drug Discov | 瞄准下一个KRAS突变-MedSci.cn
一文读懂 KRAS- MedChemExpress - 知乎
KRAS G12C inhibitor 42 | Anti-cancer Agent | MedChemExpress
Biotinylated Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer ...
阿斯利康KRAS G12D抑制剂在中国获批临床
2025 年 AACR 年会-首次披露的12款新药系列 - 知乎
New Bioprecursor Prodrugs of Sulfadiazine: Synthesis, X-ray Structure ...
AACR 2022 | KRAS Data Presentation | Novartis's KontRASt-01 Study
Xanthosine-5'-monophosphate | TargetMol
KRAS (G12D), Isoform A, His-Tag, BODIPY-GDP Loaded Recombinant KRAS ...
KRASG12D inhibition in pancreatic cancer: Fas expression facilitates ...
又有 5 款 1 类新药首次在中国获批临床_腾讯新闻
JP-2-249 | TargetMol
CP-LC-0867 | TargetMol
琼脂糖链霉亲和素磁珠 | Magrose Beads Streptavidin Ultra-suspension | TargetMol
KRAS strikes back | ApexOnco - Clinical Trials news and analysis
MNC：退回一个RAS，又从中国引进一个RAS候选新药 注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作 医疗健康 相关药物 ...
AZD5582 | Apoptosis | IAP | TargetMol
AZD-CD | AZ Series | Oriental Motor Malaysia
Amylin, amide, rat acetate | Amylin Receptor | TargetMol
AZD-KRED, AZ Series mini Driver (24 / 48 VDC)
AMG 410
KRASG12D抑制剂及其在医药上的应用的制作方法
Organic Azides: Versatile Synthons in Transition Metal‐Catalyzed C(sp2 ...
4-Chlorobutanoic acid | TargetMol
Drug Hunter - drug discovery, distilled
恒瑞医药再创国内首个！KRAS G12D抑制剂费时67天终获临床_财富号_东方财富网
AZD-KR2D | AZ系列 mini驅動器 DC電源輸入 | 台灣東方馬達
Ilunocitinib | TargetMol
AZD-KREP | AZシリーズ miniドライバ DC電源入力 | オリエンタルモーター
Wafik El-Deiry: Susan Galbraith speaks about AstraZeneca oncology ...
Yousen Jianheng Biomedical (Shanghai) Co., Ltd. (祐森健恒生物医药（上海）有限公司) - 药物 ...
AACR 落幕 | 新鲜出炉！今年又有哪些 "夺目" 的抗肿瘤新药？- MedChemExpress (MCE 中国)-公司新闻 ...
"compound 42"
Oriental Motor AZD-KD Stepping Motor Driver – NTC Tech
AZD-CD | BỘ ĐIỀU KHIỂN ĐỘNG CƠ DC ORIRENTAL AZ SERIES - A.S.C VN
AF555 NHS ester TEA salt_TargetMol
Ras antagonist | Ras inhibitor | Ras agonist | Ras activator
AZD-KED | AZ系列 | 台灣東方馬達
2-(Acetylamino)-2-deoxy-3-O-α-D-galactopyranosyl-D-galactose_TargetMol
DGM130R-AZAC / AZD-AD Hollow Rotary Actuators
AZD-KRX, AZ Series mini Driver Pulse Input Type with RS-485 ...
GSK-A | TargetMol
